135898-05-4

Upstream product

• 53254-60-7 3,7-dimethyl-1-(p-toluenesulfonyl)-2(E),6-octadiene 
• 135898-04-3 3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2-methyl-2-(5-chloro-4-methyl-3(E)-pentene)-2H-1-benzopyran 
• 135897-93-7 ethyl 5-<3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2,7,8-trimethyl-2H-1-benzopyran-2-yl>-2-methyl-2(E)-pentenoate 
• 135897-96-0 5-<3,4-dihydro-6-<(2-methoxyethoxy)methoxy>-2,7,8-trimethyl-2H-1-benzopyran-2-yl>-2-methyl-2(E)-penten-1-ol 
• 143172-86-5 (2E,6E)-8-(2,5-Dihydroxy-3,4-dimethyl-phenyl)-2,6-dimethyl-octa-2,6-dienoic acid ethyl ester 
• 135897-95-9 (E)-5-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-2-methyl-pent-2-enoic acid ethyl ester 
• 135897-92-6 ethyl (2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dienoate 
• 64218-01-5 (E)-6-hydroxy-4-methyl-4-hexenal tetrahydropyranyl ether 
• 135897-91-5 ethyl 2,6-dimethyl-8-<(tetrahydro-2H-pyran-2-yl)oxy>-2(E),6(E)-octadienoate 

Relevant academic research and scientific papers

Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders

This invention relates to the use of tocotrienol, gamma-tocotrienol and delta-tocotrienol in reducing hypercholesterolemia, hyperlipidemia and thromboembolic disorders in mammals. [The isolation of these tocotrienols from natural sources and their chemical synthesis is disclosed.] The chemical synthesis of these tocotrienols is disclosed. The present invention also relates to prodrugs and pharmaceutical compositions of gamma-tocotrienol, delta-tocotrienol and tocotrienol and uses thereof.

Hypocholesterolemic Activity of Synthetic and Natural Tocotrienols

Tocotrienols are farnesylated benzopyran natural products that exhibit hypocholesterolemic activity in vitro and in vivo.The mechanism of their hypolipidemic action involves posttranscriptional suppression of HMG-CoA reductase by a process distinct from o